Zimmer Biomet Lifts 2026 EPS to $8.47-$8.59-Real Recovery, or Just a Modest Nudge?

Zimmer's higher 2026 guide comes with a live operating checkpoint

Zimmer Biomet paired first-quarter results with raised 2026 adjusted EPS guidance of $8.47 to $8.59 and an organic growth outlook of 2.25% to 3.25%. Rather than asking investors to trust a forecast in isolation, the company is asking the market to evaluate that guide against a fresh quarter of operating data.

The bullish case: profit growth is running ahead of revenue growth

In the quarter, organic constant-currency sales grew 2.9%, while adjusted diluted earnings per share rose to $2.09, up 15.5%. That gap matters because a more credible recovery usually shows not just steadier demand, but also better earnings leverage as the business executes.

Why skepticism still makes sense

The broader orthopedic backdrop is still uneven, with Stryker's orthopedics growth at 0.1%. So the question is not whether Zimmer suddenly landed in a boom cycle. It is whether the company is improving faster than investors feared.

What the quarter shows about quality of growth

The headline sales increase matters less than the breakdown underneath it.

Organic growth is the cleaner read-through

Reported sales rose 9.3%, while constant-currency sales rose 6.8%. More importantly, organic constant-currency sales grew 2.9%. That suggests Zimmer was not relying mainly on currency or acquisition math to move the top line. It was growing from underlying surgeon activity and case demand.

Adjusted EPS rising 15.5% while organic sales grew 2.9% points to operating leverage. The business appears to be keeping more of each incremental sale, which is a better sign than revenue growth alone.

Product launches and mix can support a steadier demand pattern

Orthopedic businesses are not just one-and-done implant sellers. Better outcomes, easier workflows, and supporting consumables can help surgeons stick with a company's broader platform over time.

Zimmer's own commentary said the quarter reflected healthy end markets, continued momentum from recently launched products, and disciplined execution. That matters because new launches can improve case mix and reinforce repeat use of instruments and consumables.

Peer results give context. J&J's orthopedics group still posted 6.3% orthopedic sales growth, while Stryker showed only 0.1% growth. That spread suggests product rollout and execution can still make a difference even when the market is only moderately active.

Cash flow makes the guidance raise easier to take seriously

Guidance upgrades can be purely theoretical. Cash generation is harder to dismiss. Zimmer produced $359.4 million in operating cash flow and $245.9 million of free cash flow in the first quarter, which gives it room to keep investing in launches, support capital returns, and back the higher full-year outlook.

What would confirm or challenge Zimmer's recovery case

The next one to two quarters should show whether the guidance lift was earned or merely advertised.

The main trigger is follow-through in procedure activity

The cleanest signal is whether Zimmer continues to build on a quarter in which organic constant-currency sales grew 2.9%. Because that measure strips out acquisitions and currency, it is one of the best available read-throughs for surgeon activity and case volume.

Positive signals to watch

• Organic growth holds up: If organic constant-currency sales stay near or above the first-quarter pace, the guidance range looks more credible.
• Profit growth keeps outpacing revenue growth: That would suggest mix, pricing, and cost discipline are still helping earnings.
• Implants and related products remain firm: J&J's stronger growth versus Stryker's near-flat orthopedic sales growth shows execution can still drive differentials in a mixed market.
• Cash conversion remains strong: The first quarter's $359.4 million in operating cash flow and $245.9 million of free cash flow are a good baseline for judging operating quality.

What could weaken the thesis

• A meaningful slowdown in organic constant-currency sales from the first-quarter pace.
• Weaker core implant categories, which would call the mix story into question.
• A material drop in cash generation, which would make the business look more like a cost-management story than a true recovery.
• A peer gap that widens the wrong way, with competitors stabilizing while Zimmer fails to keep gaining traction.

One strong quarter is a clue. Two strong quarters on sales quality, mix, and cash flow are what would make the recovery case more convincing.